Biotec Pharmacon ASA appoints Dr. Jethro Holter as interim CEO

(Tromsø/Oslo 23. October 2019) Biotec Pharmacon ASA (OSE: “BIOTEC”) announced today that its Board of Directors has unanimously appointed Dr Jethro Holter as the Company’s interim Chief Executive Officer. Jethro, who currently serves as the Managing Director of ArcticZymes AS, a subsidiary of Biotec Pharmacon, will succeed Christian Jorgensen, the current CEO, effective immediately. Jethro … Continued ›

ArcticZymes launches Triton FREE version of SAN High Quality

ArcticZymes is pleased to announce the launch of SAN HQ Triton FREE. The new formulation offers the same advantages as SAN HQ, such as highly effective DNA digestion at high salt conditions, extensive quality control testing and compatibility with SAN HQ ELISA to verify the clearance of the enzyme downstream, while also ensuring EU REACH … Continued ›

Biotec and ArcticZymes featured in the September edition of MedNous

Biotec Pharmacon and ArcticZymes is featured in the September 2019 edition of MedNous, a publication of Evernow Publishing Ltd. The article introduces you to some of the background and foundation for Biotec Pharmacon, and especially ArcticZymes. The full article can be read here    

ArcticZymes expands its Triton FREE product portfolio

ArcticZymes AS is pleased to announce the launch of Cod UNG Glycerol and Triton FREE and HL-dsDNase Triton FREE. This launch is a continuing step towards maintaining a completely EU REACH compliant product portfolio after Triton X-100 becomes subject to authorisation in January 2021. The convenient glycerol-free formulation is suitable for lyophilization and automated processes. … Continued ›

Biotec Pharmacon enters a distribution agreement for Woulgan® in Austria

(Tromsø, 26 April 2019) Biotec Pharmacon’s (“Biotec”, OSE: BIOTEC) subsidiary Biotec BetaGlucans has entered into a distribution agreement for Woulgan® with the Austrian distributor Publilog GmbH (Publilog). Under the terms of the agreement, Publilog becomes an exclusive partner for distribution of Woulgan® to the Austrian market, with Biotec supporting Publilog’s marketing division. Publilog is a … Continued ›

Notice of Annual General Meeting 15 May 2019

The Annual General Meeting in Biotec Pharmacon will be held on Wednesday 15. May 2019 at 11.00 CET at Hotel Continental, Stortingsgata 24/26, Oslo. The notice, registration and proxy form will be sent to the Company’s shareholders today and made available on and here under General meetings Shareholders who wish to attende the Annual General Meeting, in person … Continued ›

Biotec Pharmacon renews contract with largest customer within Animal Health business

Tromsø, Norway, 04 April 2019 – Biotec Pharmacon’s (OSE: Biotec) subsidiary, Biotec BetaGlucans, has renewed its M-Glucan® contract with its largest customer within its Animal Health business. The Company will continue to supply and assist its long-standing customer, a major player in the Animal Health sector. Expected revenues, depending on the sales of the customer … Continued ›

Biotec Pharmacon’s subsidiary, ArcticZymes, granted €254.000 funding from Eurostars for a synthetic biology project

Tromsø, Norway, 2. April 2019 – Biotec Pharmacon (OSE: Biotec) announced today that its subsidiary, ArcticZymes, has been granted €254k as part of a collaborative project on the development of novel enzymes for synthetic biology. The project proposal was developed in collaboration with the University of Tromsø and Danish company, Legomics, has been positively evaluated … Continued ›

Biotec Pharmacon’s subsidiary, ArcticZymes launches its first ligase enzyme

Tromsø, Norway, 7 February 2019 – Biotec Pharmacon’s (OSE: Biotec) subsidiary ArcticZymes adds its first ligase enzyme, T4 DNA ligase, to its portfolio. T4 DNA ligase, the most widely used enzyme in the ligase family, works by joining DNA fragments together. It is used in the development of kits and products serving the In Vitro … Continued ›

Browse archive